Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Dec;34(12):1714–1717. doi: 10.1136/gut.34.12.1714

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

J Camps 1, S Crisóstomo 1, M García-Granero 1, J I Riezu-Boj 1, M P Civeira 1, J Prieto 1
PMCID: PMC1374469  PMID: 7904252

Abstract

Pretreatment variables that could predict the response of chronic hepatitis C to interferon alfa treatment have not been fully assessed. Eighteen baseline variables were evaluated in a series of 100 consecutive patients treated with a 12 month course of interferon alfa. For the purposes of this study, response was defined as the return to normal of aminotransferase activities before the third month of treatment. Seventy per cent of the patients responded to treatment. Six variables were associated with an increased likelihood of response assessed by univariate analysis. With stepwise multiple regression analysis assessment, however, only three variables remained independently predictive of response: low gamma glutamyltransferase (gamma GT) activities (p < 0.001), absence of obesity (p = 0.005), and absence of cirrhosis (p = 0.01). The response rate in patients with gamma GT activities < 0.66 mu kat/l (n = 55) was 78% and 60% in patients with values > 0.66 mu kat/l (n = 45) (p = 0.048). Response was attained in 75% of non-obese patients (n = 80), compared with only 50% of obese patients (n = 20) (p = 0.03). Finally, 80% of patients without cirrhosis (n = 76) responded, while among those with cirrhosis (n = 24) the response rate was only 37% (p < 0.001). All 23 patients without cirrhosis, <40 years old, and with gamma GT activities <0.66 mu kat/l responded to treatment, while only 28.5% of 14 patients with cirrhosis, >40 years old, and with gamma GT activities >0.66 mu kat/l responded to interferon alfa (p<0.001). Those findings may be useful when evaluating interferon alfa trials and it is suggested that this treatment should be applied early in the course of chronic hepatitis C.

Full text

PDF
1714

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis. 1991 Apr;163(4):882–885. doi: 10.1093/infdis/163.4.882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brook M. G., Karayiannis P., Thomas H. C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989 Nov;10(5):761–763. doi: 10.1002/hep.1840100502. [DOI] [PubMed] [Google Scholar]
  3. Camps J., Castilla A., Ruiz J., Civeira M. P., Prieto J. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol. 1993 Mar;17(3):390–396. doi: 10.1016/s0168-8278(05)80223-5. [DOI] [PubMed] [Google Scholar]
  4. Causse X., Godinot H., Chevallier M., Chossegros P., Zoulim F., Ouzan D., Heyraud J. P., Fontanges T., Albrecht J., Meschievitz C. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991 Aug;101(2):497–502. doi: 10.1016/0016-5085(91)90030-o. [DOI] [PubMed] [Google Scholar]
  5. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  6. Davis G. L. Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol. 1990;11 (Suppl 1):S72–S77. doi: 10.1016/0168-8278(90)90168-q. [DOI] [PubMed] [Google Scholar]
  7. Di Bisceglie A. M., Hoofnagle J. H. Therapy of chronic hepatitis C with alpha-interferon: the answer? Or more questions? Hepatology. 1991 Mar;13(3):601–603. doi: 10.1016/0270-9139(91)90318-p. [DOI] [PubMed] [Google Scholar]
  8. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  9. Hassner A., Kletter Y., Shlag D., Yedvab M., Aronson M., Shibolet S. Impaired monocyte function in liver cirrhosis. Br Med J (Clin Res Ed) 1981 Apr 18;282(6272):1262–1263. doi: 10.1136/bmj.282.6272.1262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Houghton M., Weiner A., Han J., Kuo G., Choo Q. L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology. 1991 Aug;14(2):381–388. [PubMed] [Google Scholar]
  11. Kong W. Y., Koldovský O., Rao R. K. Appearance of exogenous epidermal growth factor in liver, bile, and intestinal lumen of suckling rats. Gastroenterology. 1992 Feb;102(2):661–667. doi: 10.1016/0016-5085(92)90117-h. [DOI] [PubMed] [Google Scholar]
  12. Kroon C., de Boer A., Kroon J. M., Schoemaker H. C., van den Meer F. J., Cohen A. F., Schoenmaker H. C. Influence of skinfold thickness on heparin absorption. Lancet. 1991 Apr 20;337(8747):945–946. doi: 10.1016/0140-6736(91)91573-d. [DOI] [PubMed] [Google Scholar]
  13. Marcellin P., Boyer N., Giostra E., Degott C., Courouce A. M., Degos F., Coppere H., Cales P., Couzigou P., Benhamou J. P. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991 Mar;13(3):393–397. [PubMed] [Google Scholar]
  14. Marcellin P., Giostra E., Boyer N., Loriot M. A., Martinot-Peignoux M., Benhamou J. P. Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis? J Hepatol. 1990 Jul;11(1):77–79. doi: 10.1016/0168-8278(90)90275-v. [DOI] [PubMed] [Google Scholar]
  15. Martell M., Esteban J. I., Quer J., Genescà J., Weiner A., Esteban R., Guardia J., Gómez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992 May;66(5):3225–3229. doi: 10.1128/jvi.66.5.3225-3229.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McCullough A. J., Stassen W. N., Wiesner R. H., Czaja A. J. Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity. Hepatology. 1987 Jan-Feb;7(1):49–54. doi: 10.1002/hep.1840070112. [DOI] [PubMed] [Google Scholar]
  17. Okada S., Akahane Y., Suzuki H., Okamoto H., Mishiro S. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology. 1992 Sep;16(3):619–624. doi: 10.1002/hep.1840160302. [DOI] [PubMed] [Google Scholar]
  18. Panis Y., Nordlinger B., Delelo R., Herve J. P., Infante J., Kuhnle M., Ballet F. Experimental colorectal liver metastases. Influence of sex, immunological status and liver regeneration. J Hepatol. 1990 Jul;11(1):53–57. doi: 10.1016/0168-8278(90)90271-r. [DOI] [PubMed] [Google Scholar]
  19. Realdi G., Diodati G., Bonetti P., Scaccabarozzi S., Alberti A., Ruol A. Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial. J Hepatol. 1990;11 (Suppl 1):S68–S71. doi: 10.1016/0168-8278(90)90167-p. [DOI] [PubMed] [Google Scholar]
  20. Schvarcz R., Weiland O., Wejstål R., Norkrans G., Frydén A., Foberg U. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis. 1989;21(6):617–625. doi: 10.3109/00365548909021689. [DOI] [PubMed] [Google Scholar]
  21. Shindo M., Di Bisceglie A. M., Cheung L., Shih J. W., Cristiano K., Feinstone S. M., Hoofnagle J. H. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991 Nov 1;115(9):700–704. doi: 10.7326/0003-4819-115-9-700. [DOI] [PubMed] [Google Scholar]
  22. Tinè F., Magrin S., Craxì A., Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol. 1991 Sep;13(2):192–199. doi: 10.1016/0168-8278(91)90814-r. [DOI] [PubMed] [Google Scholar]
  23. Weck P. K., Leventhal B. G., Brand C., Finter N. B. Detection and incidence of neutralizing antibodies to interferon-alpha-n1. J Interferon Res. 1989 Sep;9 (Suppl 1):S37–S43. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES